--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-068579" form_type: "8-K" ticker: "IOVA" cik: "0001425205" company_name: "IOVANCE BIOTHERAPEUTICS, INC." filed_at: "2023-06-06T23:59:59+00:00" generated_at: "2026-06-14T06:30:28.774990+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.35 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Iovance Biotherapeutics shareholders approve all six proposals at 2023 annual meeting ## Summary - All seven director nominees elected; Wendy Dixon did not stand for re-election (no disagreement). - Advisory vote on executive compensation approved (152.1M for, 18.0M against). - Ratification of Ernst & Young as auditor approved (189.1M for). - Amendment to 2018 Equity Incentive Plan: shares increased from 20.7M to 29.7M. - ESPP shares increased from 500k to 1.4M; authorized common stock increased from 300M to 500M. ## SEC filing metadata - accession: 0001104659-23-068579 - form_type: 8-K - ticker: IOVA - cik: 0001425205 - company_name: IOVANCE BIOTHERAPEUTICS, INC. - filed_at: 2023-06-06T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.35 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/tm2317979d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-068579 - JSON: https://secwatch.observer/filing/0001104659-23-068579.json - Plain text: https://secwatch.observer/filing/0001104659-23-068579.txt ## Key facts - Shareholder Votes IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve an amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant from 20,700,000 shares to 29,700,000 shares at the 2023-06-06 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-06 source text: This proposal was approved with 163,183,808 "FOR" votes, 7,000,254 "AGAINST" votes and 350,333 "ABSTAIN" votes. There were 20,284,943 broker non-votes in connection with this proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm - Shareholder Votes IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2023-06-06 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-06 source text: This proposal was approved with 152,122,330 "FOR" votes, 18,005,962 "AGAINST" votes and 406,103 "ABSTAIN" votes. There were 20,284,943 broker non-votes in connection with this proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm - Shareholder Votes IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-06 source text: This proposal was approved with 189,050,447 "FOR" votes, 1,427,679 "AGAINST" votes and 341,212 "ABSTAIN" votes. There were 0 broker non-votes in connection with this proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm - Shareholder Votes IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 500,000,000 shares at the 2023-06-06 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-06-06 source text: This proposal was approved with 183,669,098 "FOR" votes, 6,762,171 "AGAINST" votes and 388,069 "ABSTAIN" votes. There were 0 broker non-votes in connection with this proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm - Shareholder Votes IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Election of Iain Dukes, D. Phil., Athena Countouriotis, M.D., Ryan Maynard, Merrill A. McPeak, Wayne P. Rothbaum, Michael Weiser, M.D., Ph.D. and Wendy Yarno to the Board of Directors at the 2023-06-06 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-06 source text: The voting results for the election of the director nominees were as follows: For Withheld Broker Non-Vote Dr. Dukes 148,807,931 21,726,464 20,284,943 Dr. Countouriotis 151,909,502 18,624,893 20,284,943 Mr. Maynard 154,930,213 15,604,182 20,284,943 General McPeak 91,979,426 78,554,969 20,284,943 Mr. Rothbaum 154,805,281 15,729,114 20,284,943 Dr. Weiser 148,314,345 22,220,050 20,284,943 Ms. Yarno 148,822,514 21,711,881 20,284,943 evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm - Shareholder Votes IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve an amendment to the 2020 Iovance Employee Stock Purchase Plan to increase the number of shares available for grant from 500,000 shares to 1,400,000 shares at the 2023-06-06 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-06 source text: This proposal was approved with 166,626,237 "FOR" votes, 3,580,244 "AGAINST" votes and 327,914 "ABSTAIN" votes. There were 20,284,943 broker non-votes in connection with this proposal. evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923068579/0001104659-23-068579-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.